A government can shorten the time it takes to authorize a clinical trial. It cannot shorten the uncertainty a patient must weigh before joining one. China’s National Medical Products Administration (NMPA) is now attempting the first without compromising the second, under an expedited pathway that could bring experimental medicines into human testing more quickly.
A Faster Route to the First Patient
The new policy, issued September 9 and published in English on October 14, 2025, requires regulators to review eligible applications to begin trials of innovative drugs within 30 working days of acceptance. It does not authorize the drugs for sale, establish that they work, or eliminate clinical testing. It accelerates one regulatory gate: permission to investigate a treatment in people.
The reform follows a pilot launched in July 2024 and builds on China's existing 60-working-day system, introduced in 2019, under which trials can proceed if regulators raise no objection. According to the NMPA's policy explanation, average reviews had already fallen to approximately 50 working days. Officials argue that further acceleration could address unmet medical needs while allowing Chinese researchers to participate earlier in global drug development.
The fast lane is selective. It covers qualifying Class 1 innovative chemical medicines, biologics, and traditional Chinese medicines—not every drug marketed as a breakthrough. Eligible applications include nationally supported projects of significant clinical value, certain pediatric or rare-disease treatments, and globally coordinated programs. Early-phase international projects qualify, while later-stage multinational trials must be led or co-led by investigators at Chinese institutions.
Developers must identify the accelerated pathway in their applications. The Center for Drug Evaluation has five working days to decide whether to accept a filing. When complex scientific questions require further consultation, regulators must notify applicants within 20 working days and may extend the review to 60 days. Companies must also assess their lead institution's ethics-review capabilities, begin ethics preparations alongside regulatory submissions, and pledge to start the trial within 12 weeks of approval—measured by the first Chinese participant signing informed consent.
The NMPA insists the accelerated process retains international safety standards and requires greater coordination among developers, investigators, and ethics committees. Yet institutional capacity remains a concern. A 2024 qualitative study of investigator-initiated trials—a different category of research—identified hospital ethics committees relying heavily on part-time members and sometimes struggling with monthly review schedules. Another study published in September 2025, drawing on questionnaires from 287 researchers and interviews with 37, identified weak oversight and competitive pressures in Chinese clinical research. Neither establishes that this new pathway is unsafe, but both raise questions about the resources needed to sustain meaningful scrutiny.
Selection also creates questions of fairness. Government-backed pipelines and well-resourced international collaborations may be better positioned to meet fast-track requirements than smaller developers. Meanwhile, a faster trial opening does not necessarily make the eventual medicine affordable, effective, or accessible. The reform can remove weeks from an application; it cannot guarantee what follows.
Two Different Ways of Counting Time
For patients, the stakes are hardly theoretical.
In a 2024 interview with China Daily, Xiao Tan, then 25 and living with hemophilia in Changsha, described borrowing medication and even using expired clotting factor when treatment was difficult to obtain.
"When there is bleeding, any medicine can be lifesaving, and expired medicine or even those for clinical trials are better than no medicine," he said.
A different young patient made a contrasting calculation. Zoe Davis, a 20-year-old university student in the United States with sickle cell disease, told Reuters in September 2024 that she was waiting before trying newly approved gene therapies: "It is so new ... I wanted to see more success stories before I committed to it."
Neither patient was commenting on China's new regulation, and they faced different illnesses and treatment options. Yet their accounts expose the danger of speaking about patient urgency as though it produces one preference. Severe need can make earlier access precious. It can also make uncertain promises harder to refuse. For another young adult, waiting for stronger evidence may itself be an informed decision.
That distinction matters particularly when pediatric and rare-disease treatments are prioritized. A regulator can promise a 30-day decision, and a sponsor can promise a consent form within 12 weeks. Neither number reveals whether a prospective participant understands the unknowns, whether a teenager's doubts were heard alongside a parent's hopes, or whether an ethics committee had sufficient time to challenge an optimistic protocol.
For a generation that has watched technologies move rapidly from experimental novelties to everyday expectations, there is a familiar danger in confusing availability with obligation. Once a treatment becomes possible, will declining it seem irrational, ungrateful, or even irresponsible?
China's new pathway may provide valuable time to those whose diseases have left them little. But speed should expand patients' choices, rather than narrow the space in which they make them. The measure of progress is not merely how quickly researchers can begin a trial, but whether its participants remain free to hesitate.
Medicine can move faster without requiring its patients to.
Explore more exclusive insights at nextfin.ai.
